New Delhi, Nov 14 (PTI) Strides Pharma Science on Monday reported a consolidated net profit of Rs 33 lakh for the second quarter ended September 30, 2022.

The drug maker had reported a net loss of Rs 168 crore in the July-September period of last year.

Also Read | France Squad for FIFA World Cup 2022 in Qatar: Team FRA Schedule & Players to Watch Out For in Football WC.

Revenue from operations rose to Rs 897 crore in the period under review as against Rs 721 crore in the year-ago period, Strides Pharma Science said in a regulatory filing.

"We continue to make good strategic progress across all our key businesses with a sharper focus on execution and cost competitiveness. We have delivered an improved sequential performance led by gross margin expansion," Strides Pharma Science Founder, Managing Director and Executive Chairperson Arun Kumar said.

Also Read | Fulham vs Manchester United, Premier League 2022-23 Free Live Streaming Online: How To Watch Premier League Match Live Telecast on TV & Football Score Updates in IST?.

The company's cost control measures have started yielding results and have enabled strong operating leverage during the quarter, he added.

"We have completed the strategic review of the other regulated markets (ORM) business. We have decided to exit several low-margin product lines resulting in a lower top line during the quarter," Kumar said.

With all the levers in place, the company expects to continue its growth momentum in coming quarters with a focus on improved margins, free cash flow generation, and significant deleveraging of the balance sheet, targeting a net debt-to-EBITDA of less than three times, he added.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)